-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Anhui Provincial Pharmaceutical Joint Procurement Office issued the "Anhui Province Partial Drug Centralized Procurement Document (AHYPDC-2021-1)", and 45 drugs were included in the procurement catalog
.
It is understood that the determination of the centralized drug procurement catalogue for this time is based on the combing of drug procurement data and expert argumentation from the Anhui Province Pharmaceutical Centralized Procurement Platform.
Forty-five varieties of oral regular-release dosage forms, sodium aescinate, and gastrodin are the varieties purchased this time
.
According to the notice, the online qualification declaration time is from 9:00 on October 25, 2021 to 17:00 on October 31, 2021.
The time and place of bidding, negotiation, and negotiation have not been disclosed yet
.
From an overall point of view, the current round of centralized procurement in Anhui is one year, and the selected companies are still selected by grouping and comprehensive bidding
.
The industry believes that from the perspective of the treatment plans for unreviewed varieties in the past, price reductions will still be the general trend of centralized procurement of drugs.
Therefore, for the unreviewed drugs that have entered the centralized procurement in Anhui Province this time, it may also usher in Great price cuts
.
Coincidentally, on October 21, the Zhejiang Pharmaceutical Equipment Procurement Center issued the "Announcement on the Second Batch of Drug Centralized Procurement of Public Medical Institutions in Zhejiang Province", announcing the start of a new round of centralized procurement
.
The current round of centralized harvesting in Zhejiang is still one year, and a total of 17 varieties including loratadine, gastrodin, and ginkgo damol have been included
.
It is worth mentioning that this round of centralized procurement in Zhejiang also adopted a method of distinguishing between Group A and Group B and comprehensive review
.
Group A is a generic drug that has passed the quality and efficacy consistency evaluation of the original research drug or reference preparation; and group B is other generic drugs
.
In fact, in addition to the above provinces, in recent years, the relevant departments have been promoting the procurement of non-overrated drugs in various regions
.
However, although some regions have begun to purchase drugs that have not passed the consistency evaluation, on the whole, it is still a major trend in the industry to suspend the online procurement function of the Sunshine Procurement Platform for products that have not passed the consistency evaluation
.
It is understood that Beijing Sunshine Purchasing Network recently issued a "Notice on Suspending the Purchasing Function of Some Products That Have Not Passed the Consistency Evaluation in the Scope of Centralized National Procurement.
"
.
According to the city’s arrangements for the implementation of the fifth batch of nationally organized drug centralized procurement, after reviewing, it was decided to suspend some of the fifth batch of national centralized procurements that failed to pass consistency from the date of implementation of the fifth batch of national centralized procurement results.
Evaluate the online purchasing function of the product on the Sunshine Purchasing Platform
.
According to the notice, the list of the fifth batch of unqualified products to be stopped contains 757 drugs
.
In this regard, the industry believes that in the future, a large number of products that fail to pass the consistency evaluation may still be difficult to gain market access.
Related small and medium-sized enterprises will gradually withdraw, and the industry concentration will be further improved
.
In this context, pharmaceutical companies need to speed up the evaluation of the consistency of generic drugs, so that the quality and efficacy of the generic drugs are consistent with the original drugs, and clinically replace the original drugs
.
In addition, we must also consider our own survival strategy, and do a good job of transformation and upgrading or innovation as soon as possible to improve the quality of China's generic drugs and the overall development level of the pharmaceutical industry, so as to better protect the safety of public use of drugs
.
.
It is understood that the determination of the centralized drug procurement catalogue for this time is based on the combing of drug procurement data and expert argumentation from the Anhui Province Pharmaceutical Centralized Procurement Platform.
Forty-five varieties of oral regular-release dosage forms, sodium aescinate, and gastrodin are the varieties purchased this time
.
According to the notice, the online qualification declaration time is from 9:00 on October 25, 2021 to 17:00 on October 31, 2021.
The time and place of bidding, negotiation, and negotiation have not been disclosed yet
.
From an overall point of view, the current round of centralized procurement in Anhui is one year, and the selected companies are still selected by grouping and comprehensive bidding
.
The industry believes that from the perspective of the treatment plans for unreviewed varieties in the past, price reductions will still be the general trend of centralized procurement of drugs.
Therefore, for the unreviewed drugs that have entered the centralized procurement in Anhui Province this time, it may also usher in Great price cuts
.
Coincidentally, on October 21, the Zhejiang Pharmaceutical Equipment Procurement Center issued the "Announcement on the Second Batch of Drug Centralized Procurement of Public Medical Institutions in Zhejiang Province", announcing the start of a new round of centralized procurement
.
The current round of centralized harvesting in Zhejiang is still one year, and a total of 17 varieties including loratadine, gastrodin, and ginkgo damol have been included
.
It is worth mentioning that this round of centralized procurement in Zhejiang also adopted a method of distinguishing between Group A and Group B and comprehensive review
.
Group A is a generic drug that has passed the quality and efficacy consistency evaluation of the original research drug or reference preparation; and group B is other generic drugs
.
In fact, in addition to the above provinces, in recent years, the relevant departments have been promoting the procurement of non-overrated drugs in various regions
.
However, although some regions have begun to purchase drugs that have not passed the consistency evaluation, on the whole, it is still a major trend in the industry to suspend the online procurement function of the Sunshine Procurement Platform for products that have not passed the consistency evaluation
.
It is understood that Beijing Sunshine Purchasing Network recently issued a "Notice on Suspending the Purchasing Function of Some Products That Have Not Passed the Consistency Evaluation in the Scope of Centralized National Procurement.
"
.
According to the city’s arrangements for the implementation of the fifth batch of nationally organized drug centralized procurement, after reviewing, it was decided to suspend some of the fifth batch of national centralized procurements that failed to pass consistency from the date of implementation of the fifth batch of national centralized procurement results.
Evaluate the online purchasing function of the product on the Sunshine Purchasing Platform
.
According to the notice, the list of the fifth batch of unqualified products to be stopped contains 757 drugs
.
In this regard, the industry believes that in the future, a large number of products that fail to pass the consistency evaluation may still be difficult to gain market access.
Related small and medium-sized enterprises will gradually withdraw, and the industry concentration will be further improved
.
In this context, pharmaceutical companies need to speed up the evaluation of the consistency of generic drugs, so that the quality and efficacy of the generic drugs are consistent with the original drugs, and clinically replace the original drugs
.
In addition, we must also consider our own survival strategy, and do a good job of transformation and upgrading or innovation as soon as possible to improve the quality of China's generic drugs and the overall development level of the pharmaceutical industry, so as to better protect the safety of public use of drugs
.
